

6V4H



DEPARTMENT OF DEFENCE LAVARACK BARRACKS MEDICAL CENTRE

To:	Therapeutic Goods Administration Drug Safety & Evaluation Branch Allen. Nicoli
Fax:	(02) 6232 8112
Tel:	(02) 6232 8125
Email:	

From:	Dr John Simpson Lavarack Barracks Medical Centre Military Post Office TOWNSVILLE QLD 4813 Tel (07) 4771 7088 Fax (07) 4771 1674
Fax:	07 47 711674
Tel:	
Email:	

SUBJECT:	Request to prescribe TAFENOQUINE		
Reference:	Date:	8 June 00	Pages (including cover): 6

IMPORTANT: This facsimile remains the property of the Defence Organisation and is subject to the jurisdiction of section 70 of the Crimes Act 1914. If you have received the facsimile in error, you are requested to immediately contact the sender by telephone so that arrangements can be made for the return of the document to the sender.

Instructions or comments:

76



**DEPARTMENT OF DEFENCE
LAVARACK BARRACKS MEDICAL CENTRE**

Lavarack Barracks
TOWNSVILLE QLD 4813

The Director
Drug Safety and Evaluation Branch
Therapeutic Goods Administration
P O Box 100
WODEN ACT 2606

Dear Sir/Madam

I request authorisation to be a prescriber of Tafenoquine, under the guidance of the Army Malaria Institute (AMI), as per enclosed endorsement.

Our facility has seen an upsurge of malaria cases due to Australia's commitment of Defence personnel to Bougainville and East Timor, with 80 cases treated since last August. A small proportion of these cases are recurrent vivax, suitable for the Tafenoquine trial proposed by AMI.

Yours sincerely

J D SIMPSON
Unit Medical Officer
Lavarack Barracks Medical Centre

Tel: 07 47 71 7068; Fax: 07 47 71 1674

8 June 2000

Department of Defence

To:	Dr. John Simpson Lavarack Barracks Medical Centre, Townsville	From:	Major S Kitchener Army Malaria Institute Gallipoli Barracks MILPO 4052
Fax:	47711674	Fax:	07 3332 4800
Tel:	47717068	Tel:	07 3332 4836
Email:		Email:	kitchener@hotmail.com
Subject: TAFENOQUINE TREATMENT PAPERWORK		Date: 07 June 2000	
Reference:		Pages (including cover): 6	

IMPORTANT: This facsimile remains the property of the Defence Organisation and is subject to the jurisdiction of section 70 of the Crimes Act 1914. If you have received the facsimile in error, you are requested to immediately contact the sender by telephone so that arrangements can be made for the return of the document to the sender.


Instructions or comments:

John,

Attached are the forms for signing and forwarding ASAP to TGA. This is purely for the treatment of recurrent vivax malaria treated IAW HPD 215 the first time – they aren't all. You shouldn't be seeing too many who were enrolled in the TQ eradication studies, but if you do, they are treated differently. This protocol is for all those who couldn't get on the TQ eradication. I have sent a flow chart of treatment, hopefully to clarify the regime against the TQ eradication group.

You need to read the endorsement of you we (AMI) are providing to TGA to prescribe TQ within certain limitations, read the Authorised Prescriber Package from TGA, fill in your name and sign the form before faxing it off and then probably send the originals also. I would recommend calling them aswell to let them know it is on it's way. I usually speak with "Nicki" on 02 62328125.

I'm around on 0407 150384.





ARMY MALARIA INSTITUTE

Weary Dunlop Dve., Gallipoli Barracks, ENOGGERA, 4152

AMI 548-7-41

AMI /00

Mr. Z Hodak
Experimental Drugs Section
Therapeutic Goods Administration
PO Box 100
WODEN ACT 2606

ENDORSEMENT TO PRESCRIBE TAFENOQUINE

The Army Malaria Institute endorses

Dr. John Simpson, Lavarack Barracks Medical Centre,

to be an authorised prescriber of Tafenoquine under the prescribing direction provided by the Institute.


Prescribing of Tafenoquine endorsed by the Army Malaria Institute

Tafenoquine is an aminoquinolone analogous to Primaquine. Primaquine is presently recommended by the Army Malaria Institute (AMI) for the eradication and treatment of Vivax Malaria. Tafenoquine has been trialed by AMI in both Bougainville and East Timor for eradication and treatment. It has been found to be effective and safe. This supports trials conducted by SmithKline Beecham, the manufacturer of Tafenoquine.

AMI directs prescribing of Tafenoquine for the purposes of treating recurrent Vivax Malaria in Defence Personnel after initial treatment with Chloroquine (IAW HPD215). For endorsement to prescribe Tafenoquine in treatment of recurrent Vivax Malaria, the following requirements must be met by the endorsed and prescribing medical officer:

- Discussion of each case with the AMI Medical Officer on call (T: 0407 150384),
- Diagnosis of recurrent Vivax Malaria and the primary episode of Vivax Malaria must be confirmed to AMI (to the satisfaction of the OC Clinical Field, AMI) prior to use of Tafenoquine,
- The case will be treated with Chloroquine initially IAW HPD215,
- The patient will be informed of the nature and potential side effects of Tafenoquine and this is to be recorded in the Patient Medical Documents,
- Tafenoquine treatment is to begin prior to any further evidence of Vivax Malaria (usually within one week of concluding Chloroquine treatment),

- The protocol for Tafenoquine shall be:
 - 200mg base daily for three days
 - followed by 200mg base weekly for eight weeks.
- Provision of blood samples are required:
 - Prior to onset of treatment with Chloroquine (IAW HPD215), Smear, FBC, LFT
 - Following treatment with Chloroquine, immediately prior to onset of treatment with Tafenoquine, Smear, FBC, LFT
 - Following treatment with Tafenoquine, 12 hours after the final dose (including separation of plasma for drug levels), Smear, FBC, LFT, plasma for TQ levels
 - At week 2 and week 6 after commencement of the loading dose samples should be collected within 2 hrs of receiving the next weekly dose (ie., trough steady-state levels of Tafenoquine), Smear, FBC, LFT, plasma for TQ levels
 - At week 4 and week 8 after commencement of the loading dose samples should also be collected at about 12 hours post-dose (ie., peak steady-state Tafenoquine levels), Smear, FBC, LFT, plasma for TQ levels and
 - On the occurrence of any intercurrent illness requiring medical attention during the course of the treatment program, Smear, FBC, LFT, plasma for TQ levels or
 - In the event of any recurrence of Vivax Malaria in the following 12 months Smear, FBC, LFT, plasma for TQ levels.



M D EDSTEIN
LTCOL
DEPUTY DIRECTOR, AMI

Tel: 07 3332 4930; Fax: 07 3332 4800

14 April 2000

90'd 70101

AGREEMENT TO TREATMENT DIRECTIONS

AUTHORISATION OF PRESCRIBERS UNDER SECTION 19(5) OF THE THERAPEUTIC GOODS ACT 1989

Unregistered drug to be supplied (prescribed): TAKEND DIVINE.

Route of administration / dosage form: ORAL.

Condition / reason for prescribing: RECURRENT VIBRANT MALARIA.

Supplier's name and address: 51K-B. / AMI.

Name of Body endorsing this application: ARMY MALARIA INSTITUTE.

I understand that:

the product is not registered for marketing in Australia and that the Therapeutic Goods Administration (TGA) is unable to vouch for the quality, safety or efficacy of this unregistered product, and that its use is regarded as experimental.

the giving of an authority under subsection 19(5) does not render the Commonwealth, the Secretary or a delegate of the Secretary liable to a person in respect of loss, damage, or injury of any kind suffered by the person as a result of, or arising out of the use of, therapeutic goods by that person or another person.

the product may be prescribed only for patients in an authorised prescriber immediate care.

an authorised prescriber must continue to have an appropriate endorsement in order to supply the drug.

That is, an authorised prescriber must be a medical practitioner engaged in clinical practice at a hospital and having the endorsement of the ethics committee of that hospital for the purpose of supply of that drug; or a medical practitioner endorsed by a relevant specialist medical college or specialist medical society for the purpose of supply of the drug.

the Secretary of the Department of Health and Aged Care may give notice of revocation of this authorisation at any time and that any authorisation would be valid only until revoked or until the specified product or a similar product is registered in Australia, whichever is the earlier.

I agree to:

obtain from each patient (or guardian) consent in relation to the proposed use of the unregistered product, and in this context, inform the patient that the product is not registered in Australia.

report any suspected adverse reactions to the TGA.

to provide the TGA with a quarterly report on the number of patients for whom I have prescribed the product.

to comply with all relevant State/Territory legislation.

Signature: _____

Date: _____

7 JUNE, 2000

Medical Practitioner's name and address.

Dr John Simpson
 Lavarack Barracks Medical Centre
 Military Post Office
 TOWNSVILLE QLD 4813
 Tel (07) 4771 7088
 Fax (07) 4771 1674